Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
Launched by JAEB CENTER FOR HEALTH RESEARCH · Jul 21, 2009
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Both patching and atropine are accepted treatment modalities for the management of moderate amblyopia in children.1 Many practitioners prescribe 2 hours daily patching as initial therapy for amblyopia. However, many children fail to achieve normal visual acuity in the amblyopic eye with this regimen. In a randomized trial conducted by PEDIG comparing patching regimens, 71 of 92 patients with moderate amblyopia (77%) had amblyopic eye visual acuity of 20/32 or worse after 4 mo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Major Eligibility Criteria for Run-in Phase
- • Age 3 to \< 8 years
- • Amblyopia associated with strabismus, anisometropia, or both
- • Visual acuity in the amblyopic eye between 20/50 and 20/400 inclusive
- • Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \>3 logMAR lines
- * Amblyopia treatment within the past 6 months subject to the following stipulations:
- • No more than 6 weeks of any amblyopia treatment other than spectacles (except for patients being treated with 2 hours of patching per day who are entering the study on treatment)
- • No simultaneous treatment with patching and atropine
- • No use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D
- * Maximum level of treatment within the past 6 months:
- • Patching: up to 2 hours daily
- • Atropine: up to once daily
- • Wearing spectacles with optimal correction (if applicable); if amblyopic eye acuity is 20/80 or better, then VA must be stable in glasses. If amblyopic eye acuity is 20/100 or worse, then spectacles and patching can be initiated simultaneously.
- Eligibility Criteria for Randomization:
- • Amblyopic eye acuity of 20/40 to 20/160 with an inter-ocular difference of \>2 lines, or amblyopic eye acuity of 20/32 with 3 lines of IOD.
- • Reasonable compliance with prescribed treatment, defined as wearing the patch at least 10 hours per week.
- Exclusion Criteria:
- • Currently using vision therapy or orthoptics
- • Ocular cause for reduced visual acuity (nystagmus per se does not exclude the patient if the above visual acuity criteria are met)
- • Prior intraocular or refractive surgery
- • Known skin reaction to patch or bandage adhesives
About Jaeb Center For Health Research
The Jaeb Center for Health Research is a leading nonprofit organization dedicated to advancing medical research through innovative clinical trials and data analysis. With a strong emphasis on improving patient outcomes, the Center collaborates with healthcare professionals and institutions to conduct rigorous studies across various therapeutic areas, particularly in ophthalmology and diabetes. By leveraging cutting-edge methodologies and a commitment to ethical research practices, the Jaeb Center strives to enhance the understanding of disease mechanisms and develop effective treatment options, ultimately contributing to the improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fullerton, California, United States
Durham, North Carolina, United States
Patients applied
Trial Officials
David K. Wallace, M.D.
Study Chair
Duke University Eye Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials